Orgenesis Inc. (NASDAQ:ORGS) and Adaptimmune Therapeutics plc (NASDAQ:ADAP), both competing one another are Biotechnology companies. We will compare their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis Inc.	18.66M	3.96	19.18M	-1.40	0.00
Adaptimmune Therapeutics plc	59.51M	7.55	95.51M	-0.93	0.00

Table 1 highlights Orgenesis Inc. and Adaptimmune Therapeutics plc’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us Orgenesis Inc. and Adaptimmune Therapeutics plc’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Orgenesis Inc.	-102.79%	-70.9%	-31.2%
Adaptimmune Therapeutics plc	-160.49%	-44.4%	-35.4%

Risk & Volatility

A beta of 1.37 shows that Orgenesis Inc. is 37.00% more volatile than Standard & Poor’s 500. Competitively, Adaptimmune Therapeutics plc is 32.00% more volatile than Standard & Poor’s 500, because of the 1.32 beta.

Liquidity

Orgenesis Inc. has a Current Ratio of 1.8 and a Quick Ratio of 1.7. Competitively, Adaptimmune Therapeutics plc’s Current Ratio is 8.8 and has 8.8 Quick Ratio. Adaptimmune Therapeutics plc’s better ability to pay short and long-term obligations than Orgenesis Inc.

Analyst Ratings

Recommendations and Ratings for Orgenesis Inc. and Adaptimmune Therapeutics plc can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Orgenesis Inc.	0	0	0	0.00
Adaptimmune Therapeutics plc	0	0	1	3.00

Meanwhile, Adaptimmune Therapeutics plc’s average price target is $16, while its potential upside is 272.96%.

Institutional and Insider Ownership

Orgenesis Inc. and Adaptimmune Therapeutics plc has shares held by institutional investors as follows: 2.8% and 66.5%. Insiders held roughly 26.45% of Orgenesis Inc.’s shares. Competitively, insiders own roughly 0.22% of Adaptimmune Therapeutics plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Orgenesis Inc.	-0.77%	19.44%	-9.63%	-18.23%	-35.5%	10.26%
Adaptimmune Therapeutics plc	-11.23%	-12.32%	-17.09%	-58.54%	-46.89%	-25.74%

For the past year Orgenesis Inc. has 10.26% stronger performance while Adaptimmune Therapeutics plc has -25.74% weaker performance.

Summary

Adaptimmune Therapeutics plc beats Orgenesis Inc. on 6 of the 11 factors.

Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and GMP contract manufacturing services. Its Cellular Therapy Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin-producing cells for patients with diabetes. Orgenesis Inc. has a collaboration agreement with Biosequel LLC to carry out clinical trials and market its products in Russia, Belarus, and Kazakhstan. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.